Cargando…

Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial

Psoriasis is a kind of chronic inflammatory skin disease characterized by erythema, skin hyperplasia, scales and keratinocyte hyperproliferation. Psoriasis Vulgaris, the most common kind of psoriasis, severely deteriorates the life quality of patients. Traditional Chinese Medicine (TCM) is a good ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Yue, Zhang, Weishu, Li, Guanru, Guo, Xinwei, Qu, Jianhua, Lan, Haibing, Zhang, Cang, Xu, Jingna, Sun, Liyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666198/
https://www.ncbi.nlm.nih.gov/pubmed/36397446
http://dx.doi.org/10.1097/MD.0000000000031784
_version_ 1784831450450755584
author Qiu, Yue
Zhang, Weishu
Li, Guanru
Guo, Xinwei
Qu, Jianhua
Lan, Haibing
Zhang, Cang
Xu, Jingna
Sun, Liyun
author_facet Qiu, Yue
Zhang, Weishu
Li, Guanru
Guo, Xinwei
Qu, Jianhua
Lan, Haibing
Zhang, Cang
Xu, Jingna
Sun, Liyun
author_sort Qiu, Yue
collection PubMed
description Psoriasis is a kind of chronic inflammatory skin disease characterized by erythema, skin hyperplasia, scales and keratinocyte hyperproliferation. Psoriasis Vulgaris, the most common kind of psoriasis, severely deteriorates the life quality of patients. Traditional Chinese Medicine (TCM) is a good choice for the treatment of psoriasis, which has been proved to be safe and effective, and may reduce the recurrence rate. In clinical practice, Liangxue Jiedu Runzhi (LJR) ointment can effectively treat mild and moderate psoriasis with blood-heat syndrome, but there is a lack of evidence-based medical evidence. This trial aims to evaluate the efficacy and safety of LJR ointment for the treatment of mild and moderate psoriasis with blood-heat syndrome. METHODS: A multicenter, randomized, double-blind, placebo-controlled, and self-controlled clinical trial was carried out according to this paper. The symmetrical rashes of each subject were regarded as the target lesions and were randomly divided into a treatment group (LJR ointment group) and a control group (placebo group). The LJR ointment or placebo ointment were externally administered on bilateral symmetric rashes, twice a day for eight weeks. The follow-up examination was made for subjects every two weeks. The primary research finding was conveyed by Psoriasis Area and Severity Index (PASI) in 8 weeks. The secondary research finding includes adverse events. RESULTS: 46 subjects undergo this research project. The difference between PASI scores of the target lesions in the treatment group and control group is statistically significant were in 8 weeks (P < .001). The percentage of PASI 75 in treatment group and control group were 48% and 15% in week 8, respectively (x(2) = 11.33, P < .05). No severe adverse events were reported. CONCLUSIONS: LJR ointment was proved to have efficacy in the treatment of mild and moderate psoriasis with the blood-heat syndrome.
format Online
Article
Text
id pubmed-9666198
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-96661982022-11-16 Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial Qiu, Yue Zhang, Weishu Li, Guanru Guo, Xinwei Qu, Jianhua Lan, Haibing Zhang, Cang Xu, Jingna Sun, Liyun Medicine (Baltimore) 4000 Psoriasis is a kind of chronic inflammatory skin disease characterized by erythema, skin hyperplasia, scales and keratinocyte hyperproliferation. Psoriasis Vulgaris, the most common kind of psoriasis, severely deteriorates the life quality of patients. Traditional Chinese Medicine (TCM) is a good choice for the treatment of psoriasis, which has been proved to be safe and effective, and may reduce the recurrence rate. In clinical practice, Liangxue Jiedu Runzhi (LJR) ointment can effectively treat mild and moderate psoriasis with blood-heat syndrome, but there is a lack of evidence-based medical evidence. This trial aims to evaluate the efficacy and safety of LJR ointment for the treatment of mild and moderate psoriasis with blood-heat syndrome. METHODS: A multicenter, randomized, double-blind, placebo-controlled, and self-controlled clinical trial was carried out according to this paper. The symmetrical rashes of each subject were regarded as the target lesions and were randomly divided into a treatment group (LJR ointment group) and a control group (placebo group). The LJR ointment or placebo ointment were externally administered on bilateral symmetric rashes, twice a day for eight weeks. The follow-up examination was made for subjects every two weeks. The primary research finding was conveyed by Psoriasis Area and Severity Index (PASI) in 8 weeks. The secondary research finding includes adverse events. RESULTS: 46 subjects undergo this research project. The difference between PASI scores of the target lesions in the treatment group and control group is statistically significant were in 8 weeks (P < .001). The percentage of PASI 75 in treatment group and control group were 48% and 15% in week 8, respectively (x(2) = 11.33, P < .05). No severe adverse events were reported. CONCLUSIONS: LJR ointment was proved to have efficacy in the treatment of mild and moderate psoriasis with the blood-heat syndrome. Lippincott Williams & Wilkins 2022-11-11 /pmc/articles/PMC9666198/ /pubmed/36397446 http://dx.doi.org/10.1097/MD.0000000000031784 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 4000
Qiu, Yue
Zhang, Weishu
Li, Guanru
Guo, Xinwei
Qu, Jianhua
Lan, Haibing
Zhang, Cang
Xu, Jingna
Sun, Liyun
Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial
title Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial
title_full Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial
title_fullStr Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial
title_full_unstemmed Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial
title_short Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial
title_sort liangxue jiedu runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: a double-blind randomized controlled trial
topic 4000
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666198/
https://www.ncbi.nlm.nih.gov/pubmed/36397446
http://dx.doi.org/10.1097/MD.0000000000031784
work_keys_str_mv AT qiuyue liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial
AT zhangweishu liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial
AT liguanru liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial
AT guoxinwei liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial
AT qujianhua liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial
AT lanhaibing liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial
AT zhangcang liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial
AT xujingna liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial
AT sunliyun liangxuejiedurunzhiointmentinthetreatmentofmildandmoderatepsoriasiswithbloodheatsyndromeadoubleblindrandomizedcontrolledtrial